La dignidad, epistema de los derechos fundamentales

El presente trabajo se titula: “LA DIGNIDAD, EPISTEMA DE LOS DERECHOS FUNDAMENTALES”, por lo cual se ha visto pertinente para la delimitación estructuración de la presente investigación, soslayar la siguiente cuestión ¿De qué manera, la falta de concesión de medida cautelares en la tramitación de los procesos constitucionales, incide en la protección de los derechos fundamentales?; para ello es menester plantear el siguiente objetivo establecer la manera en que, la falta de concesión de medida cautelares en la tramitación de los procesos constitucionales, incide en la protección de los derechos fundamentales En el capítulo II se desarrolló el marco teórico que comprende el estudio de la dignidad de las personas, así como las medidas cautelares tanto en los procesos de acción de amparo como en el de habeas corpus En el capítulo III se desarrolló el marco metodológico, para lo cual se investigación bajo un enfoque misto, es decir cualitativo y cuantitativo, dentro de un nivel de investigación descriptivo, de tipo aplicada, utilizando las técnicas de investigación como el análisis documental y las encuestas a los operadores jurídicos, utilizando para ello una muestra de 5 Jueces constitucionales, 15 fiscales penales, y 40 abogados especialistas en derecho constitucional En el capítulo IV se desarrolló la conclusión y recomendación de la presente investigación, para lo cual, se pudo efectuar la comprobación de las hipótesis postuladas al problema de investigación, concluyéndose de que la falta de concesión de medida cautelares en la tramitación de los procesos constitucionales incide negativamente en la protección de los derechos fundamentales.Tesi

Investigación en sistemas de trading, una propuesta para mejorar el desempeño de las AFOREs en México

El principal objetivo de un sistema de trading es maximizar sus beneficios utilizando señales y confirmaciones de tendencia que ayuden a mejorar el porcentaje de entradas y salidas apropiadas. En este proyecto, la fuente de estas señales proviene de un modelo de inteligencia artificial, específicamente una red neuronal multicapa. El entrenamiento del modelo utiliza datos diarios de contratos futuros continuos. Para mejorar el desempeño del sistema se tomó en cuenta un criterio de selección e importancia de variables con base a la estadística, así como una optimización de los hiper parámetros del modelo. Con el fin de disminuir la minusvalía de las posiciones abiertas, se propuso la implementación de una cobertura dinámica. Dicha cobertura se ejecutó con opciones para preservar el capital y gestionar el riesgo. El impacto de esta investigación se dirigió a contribuir e innovar el proceso de estrategias de inversión que realizan actualmente los fondos de pensión (AFORES) en México. Siendo el rendimiento un factor determinante para el retiro de futuras generaciones, y tomando en cuenta el contexto actual y recientes reformas en la materia, las estrategias de inversión apoyadas en tecnología se ha convertido en un área de suma importancia para nuestra sociedad.ITESO, A.C

Un estudio de estereotipos de género en alumnado de secundaria en el marco de Proyecto Meitner

[ES] Este artículo presenta Proyecto Meitner como una acción de divulgación científica diseñada para abordar, entre otras cuestiones, la problemática de las mujeres en Física a través de las artes escénicas. Se presenta, también, un estudio de sesgos y estereotipos de género en ciencia realizado al alumnado de los centros de secundaria de la Comunitat Valenciana que participaron en dos sesiones matinales de la obra de teatro Proyecto Meitner. Se utilizó un cuestionario que rellenaron 134 estudiantes estudiantes antes de las funciones. Las respuestas revelan una perpetuación de los estereotipos asociados al personal científico, definido principalmente como muy inteligente, culto, occidental, hombre, mayor, solitario y con bata. Además, el alumnado encuestado cree que los chicos tienen mejores aptitudes que las chicas para las carreras universitarias aun cuando las capacidades en ambos casos son las mismas

Conferencia internacional. Desafíos de la Investigación e innovación en tiempos de Covid-19

En 2018, Treinta y nueve estudiantes femeninas del X ciclo del periodo 2018-1 de la escuela de Psicología de una universidad particular del cono norte de Lima, ellas han descrito el romance de su personas cercanas a ellas. Se analizaron los 266 casos de parejas de enamorados estaban el rango de 17 a 25 años. El instrumento que se usó fue una CUESTIONARIO CUPIDO que es una escala nominal de conductas donde las estudiantes de psicología clasificaban los comportamientos en categorías preestablecidas, claramente definidas y mutuamente excluyentes. La conclusión más importante del estudio observacional fue que las parejas analizadas en un 64.4 % la mujer ero atrajo al varón y después el varón emo conectó con la mujer. También han observado otro estilo de romance cuando el varón ero atrajo a la mujer por su cuerpo atracción y después la mujer fue la que emo conectó con el varón y observaron este hecho en un 35.6 % de los casos

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

Funder: laura and john arnold foundationBACKGROUND: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). METHODS: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. RESULTS: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. CONCLUSIONS: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

RICORS2040 : The need for collaborative research in chronic kidney disease

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Mitochondrial physiology

As the knowledge base and importance of mitochondrial physiology to evolution, health and disease expands, the necessity for harmonizing the terminology concerning mitochondrial respiratory states and rates has become increasingly apparent. The chemiosmotic theory establishes the mechanism of energy transformation and coupling in oxidative phosphorylation. The unifying concept of the protonmotive force provides the framework for developing a consistent theoretical foundation of mitochondrial physiology and bioenergetics. We follow the latest SI guidelines and those of the International Union of Pure and Applied Chemistry (IUPAC) on terminology in physical chemistry, extended by considerations of open systems and thermodynamics of irreversible processes. The concept-driven constructive terminology incorporates the meaning of each quantity and aligns concepts and symbols with the nomenclature of classical bioenergetics. We endeavour to provide a balanced view of mitochondrial respiratory control and a critical discussion on reporting data of mitochondrial respiration in terms of metabolic flows and fluxes. Uniform standards for evaluation of respiratory states and rates will ultimately contribute to reproducibility between laboratories and thus support the development of data repositories of mitochondrial respiratory function in species, tissues, and cells. Clarity of concept and consistency of nomenclature facilitate effective transdisciplinary communication, education, and ultimately further discovery